Compass Therapeutics
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact
A novel class of Innate Cell Engagers targeting NKp30
A novel class of Innate Cell Engagers targeting NKp30
Post navigation
Previous Post
Previous
Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies
Next Post
Next
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact